From the AP,
Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joined the race for an easy-to-use medication to treat the coronavirus.
Currently most COVID-19 treatments require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.
Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months.
When will Paxlovid be given an EUA from the FDA?
This question resolves positively on the date during which Paxlovid (also known under PF-07321332, referenced in this article or any product containing PF-07321332 receives an Emergency Use Authorization (EUA) or full approval from the FDA for treating COVID-19.